Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine.

Matejin S, Bukreyeva N, Radosevic D, Sencanski M, Mantlo E, Veljkovic V, Glisic S, Paessler S.

Antivir Ther. 2020 Feb 28. doi: 10.3851/IMP3348. [Epub ahead of print]

PMID:
32108589
2.

Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action.

Bondžić AM, Senćanski MV, Vujačić Nikezić AV, Kirillova MV, André V, Kirillov AM, Bondžić BP.

J Inorg Biochem. 2020 Apr;205:110990. doi: 10.1016/j.jinorgbio.2019.110990. Epub 2020 Jan 7.

PMID:
32035286
3.

Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR).

Sencanski M, Glisic S, Šnajder M, Veljkovic N, Poklar Ulrih N, Mavri J, Vrecl M.

Sci Rep. 2019 Nov 12;9(1):16555. doi: 10.1038/s41598-019-52934-8.

4.

Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.

Jovanović M, Zhukovsky D, Podolski-Renić A, Domračeva I, Žalubovskis R, Senćanski M, Glišić S, Sharoyko V, Tennikova T, Dar'in D, Pešić M, Krasavin M.

Eur J Med Chem. 2019 Nov 1;181:111580. doi: 10.1016/j.ejmech.2019.111580. Epub 2019 Aug 1.

PMID:
31400708
5.

Pd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identification.

Bjelogrlić SK, Todorović TR, Kojić M, Senćanski M, Nikolić M, Višnjevac A, Araškov J, Miljković M, Muller CD, Filipović NR.

J Inorg Biochem. 2019 Oct;199:110758. doi: 10.1016/j.jinorgbio.2019.110758. Epub 2019 Jun 26.

PMID:
31299379
6.

Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets.

Stevanovic S, Sencanski M, Danel M, Menendez C, Belguedj R, Bouraiou A, Nikolic K, Cojean S, Loiseau PM, Glisic S, Baltas M, García-Sosa AT.

Molecules. 2019 Apr 2;24(7). pii: E1282. doi: 10.3390/molecules24071282.

7.

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.

Radosevic D, Sencanski M, Perovic V, Veljkovic N, Prljic J, Veljkovic V, Mantlo E, Bukreyeva N, Paessler S, Glisic S.

Front Cell Infect Microbiol. 2019 Mar 26;9:67. doi: 10.3389/fcimb.2019.00067. eCollection 2019.

8.

Functional characterization of β2-adrenergic and insulin receptor heteromers.

Susec M, Sencanski M, Glisic S, Veljkovic N, Pedersen C, Drinovec L, Stojan J, Nøhr J, Vrecl M.

Neuropharmacology. 2019 Jul 1;152:78-89. doi: 10.1016/j.neuropharm.2019.01.025. Epub 2019 Jan 29.

PMID:
30707913
9.

In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum.

Stevanović S, Perdih A, Senćanski M, Glišić S, Duarte M, Tomás AM, Sena FV, Sousa FM, Pereira MM, Solmajer T.

Molecules. 2018 Mar 27;23(4). pii: E772. doi: 10.3390/molecules23040772.

10.

Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in Chronic Tinnitus.

Bojić T, Perović VR, Senćanski M, Glišić S.

Front Neurosci. 2017 Nov 14;11:636. doi: 10.3389/fnins.2017.00636. eCollection 2017.

11.

Ibuprofen as a template molecule for drug design against Ebola virus.

Paessler S, Huang C, Sencanski M, Veljkovic N, Perovic V, Glisic S, Veljkovic V.

Front Biosci (Landmark Ed). 2018 Jan 1;23:947-953.

PMID:
28930583
12.

Assessing the dispersive and electrostatic components of the selenium-aromatic interaction energy by DFT.

Senćanski M, Djordjević I, Grubišić S.

J Mol Model. 2017 May;23(5):162. doi: 10.1007/s00894-017-3330-z. Epub 2017 Apr 15.

PMID:
28412768
13.

Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets.

Glisic S, Sencanski M, Perovic V, Stevanovic S, García-Sosa AT.

Molecules. 2016 May 5;21(5). pii: E589. doi: 10.3390/molecules21050589.

14.

Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3.

Glišić S, Cavanaugh DP, Chittur KK, Sencanski M, Perovic V, Bojić T.

BMC Bioinformatics. 2016 Mar 22;17:139. doi: 10.1186/s12859-016-0988-7.

15.

Natural Products as Promising Therapeutics for Treatment of Influenza Disease.

Sencanski M, Radosevic D, Perovic V, Gemovic B, Stanojevic M, Veljkovic N, Glisic S.

Curr Pharm Des. 2015;21(38):5573-88. Review.

PMID:
26429712
16.

In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.

Veljkovic V, Goeijenbier M, Glisic S, Veljkovic N, Perovic VR, Sencanski M, Branch DR, Paessler S.

F1000Res. 2015 May 1;4:104. doi: 10.12688/f1000research.6436.1. eCollection 2015.

17.

In silico analysis suggests interaction between Ebola virus and the extracellular matrix.

Veljkovic V, Glisic S, Muller CP, Scotch M, Branch DR, Perovic VR, Sencanski M, Veljkovic N, Colombatti A.

Front Microbiol. 2015 Feb 19;6:135. doi: 10.3389/fmicb.2015.00135. eCollection 2015.

18.

Molecular modeling of 5HT2A receptor - arylpiperazine ligands interactions.

Sencanski M, Sukalovic V, Shakib K, Soskic V, Dosen-Micovic L, Kostic-Rajacic S.

Chem Biol Drug Des. 2014 Apr;83(4):462-71.

PMID:
24772489
19.
20.

Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model.

Sukalovic V, Soskic V, Sencanski M, Andric D, Kostic-Rajacic S.

J Mol Model. 2013 Apr;19(4):1751-62. doi: 10.1007/s00894-012-1731-6. Epub 2013 Jan 9.

PMID:
23300056

Supplemental Content

Loading ...
Support Center